34,946 Shares in Evolus, Inc. (NASDAQ:EOLS) Acquired by Natixis

Natixis purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 1st quarter, Holdings Channel.com reports. The fund purchased 34,946 shares of the company’s stock, valued at approximately $489,000.

A number of other hedge funds have also modified their holdings of EOLS. Perceptive Advisors LLC boosted its stake in Evolus by 166.8% in the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after purchasing an additional 2,477,623 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Evolus during the first quarter worth $11,628,000. Vanguard Group Inc. grew its stake in Evolus by 37.9% during the third quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock valued at $24,666,000 after acquiring an additional 741,451 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Evolus by 84.2% in the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its holdings in Evolus by 3.0% in the 4th quarter. Stonepine Capital Management LLC now owns 5,333,004 shares of the company’s stock valued at $56,157,000 after acquiring an additional 154,000 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $12.31 on Friday. The firm has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $12.56. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96. Evolus, Inc. has a 52 week low of $7.44 and a 52 week high of $15.43.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $59.33 million during the quarter, compared to analyst estimates of $58.78 million. As a group, sell-side analysts predict that Evolus, Inc. will post -0.61 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 16,051 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $12.72, for a total value of $204,168.72. Following the sale, the insider now owns 673,563 shares of the company’s stock, valued at $8,567,721.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director David N. Gill sold 3,643 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $12.72, for a total value of $46,338.96. Following the sale, the director now directly owns 40,682 shares in the company, valued at $517,475.04. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Moatazedi sold 16,051 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $12.72, for a total value of $204,168.72. Following the sale, the insider now directly owns 673,563 shares of the company’s stock, valued at $8,567,721.36. The disclosure for this sale can be found here. Insiders sold 184,895 shares of company stock valued at $2,384,720 over the last three months. 6.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on EOLS shares. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Thursday, June 20th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Tuesday, May 21st.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.